Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two cases of disseminated atypical tuberculosis are presented in which the infection anteceded by over four years the development of acute granulocytic leukemia on one and Hodgkin's Disease in the other patient. The presence of disseminated atypical mycobacteriosis in the absence of a clearcut underlying illness suggests a "preneoplastic state." It should alert the clinician to the possibility of a neoplastic disorder which may not become clinically manifest for several years.
 ...
PMID:Disseminated atypical tuberculosis-antedating the clinical onset of neoplasia. 26 97

Three patients developing acute myeloid leukaemia after treatment for Hodgkin's disease are reported. They appeared among 153 patients treated since 1971. All three patients were treated with high-voltage radiation of large target volumes as well as multiple-drug chemotherapy. In two of the patients chromosomal analyses of the leukaemic bone marrow cells were performed by modern banding technique. Chromosome abnormalities were found in both patients. The value of cytogenetic analysis with the new staining techniques for elucidating the mechanism of leukaemogenesis in Hodgkin's disease is discussed.
 ...
PMID:Hodgkin's disease and acute leukaemia. A clinical and cytogenetic study. 26 92

Progressive thrombocytopenia developed in a patient following the completion of total lymphoid irradiation and combination chemotherapy for Hodgkin's disease. Thorough evaluation eventually yielded a diagnosis of acute myelogenous leukemia (AML). Previous workers have suggested that the development of thrombocytopenia with a hypoplastic marrow following total lymphoid irradiation indicated recurrent Hodgkin's disease. When the combination cytopenias and hypoplastic marrow is recognized these workers have recommended early combination chemotherapy. Recent data suggest a 1300-fold increase in the risk of AML following multimodality therapy for Hodgkin's disease. We feel that a careful search for AML should be conducted in patients with deteriorating hematologic parameters following therapy for Hodgkin's disease and that this search should include sampling bone marrow outside irradiated areas.
 ...
PMID:Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease. 27 May 97

Creation of an artificial subcutaneous arteriovenous fistula was attempted in five patients with malignant haematological disorders (two with Hodgkin's disease, two with acute lymphatic leukaemia, and one with acute myeloid leukaemia). The average time from the start of treatment to attempted creation of the fistulae was four years. Neither direct arteriovenous anastomosis nor an interposition mandril graft was successful in any patient. Failure was attributed to impaired venous run-off secondary to previous episodes of thrombophlebitis induced by the intravenous administration of cytotoxic drugs. The use of an arteriovenous fistula early in the course of the disease might minimize these later problems.
 ...
PMID:The creation of artificial subcutaneous arteriovenous fistulas in patients with malignant haematological disease. 27 5

Specificity of TdT5 as a marker for ALL was evaluated by determining its activity in cells from normal control subjects and from 35 pediatric patients with ALL, AML, Hodgkin's disease and disseminated Burkitt's lymphoma. We evaluated the DNA polymerase activity, cell surface phenotypes (E rosettes, EAC rosettes, Smlg and la-like, HTLA and cALL antigens), and hematological and cytochemical characteristics in both the normal and patient groups. DNA polymerase alpha + beta and DNA polymerase gamma activity were indiscriminately high in all immature cells as found in ALL, AML, Burkitt's lymphoma and phytohemagglutinin-stimulated normal lymphocytes, when compared to mature leukocytes found in normal individuals or in patients whose cancer was in remission. High TdT activity was found in 24 of 26 T and non-T/non-B ALL patients in active phase as well as in two of three AML patients one of whom had Auer rods. Thus, TdT, although valuable for monitoring ALL patients, may have limitations in separating AML from ALL.
 ...
PMID:High terminal deoxynucleotidyl transferase activity in pediatric patients with acute lymphocytic and acute myelocytic leukemias. 27 33

Acute myelogenous leukemia 11 years after successful treatment of Hodgkin's disease: A contribution to the problem of second malignancies. The occurence of a therapy resistant acute myelogenous leukemia 11 years after successful treatment (operation, radiotherapy, polychemotherapy) of Hodgkin's disease is described. While this second malignancy was rarely seen in the era of minimal or no therapy of Hodgkin's disease, it is nowadays described more often. The possible causes of this second malignant tumor are discussed. Although modern therapy of Hodgkin's disease should not be abandoned from fear of second malignancies, any change in primary treatment must consider not only acute toxicity but also the occurence of late second malignant tumors. Long term follow-up of all patients treated with radiotherapy and/or polychemotherapy is necessary.
 ...
PMID:[Acute myelogenous leukemia 11 years after successful treatment of Hodgkin's disease. A contribution to the problem of secondary tumors]. 27 96

Spontaneous sister chromatid exchanges and banded karyotypes were studied in blood lymphocytes from 96 individuals: seven patients with chronic myelogenous leukemia, 15 normal controls, and five "cancer families" comprising 12 cancer patients, 40 tumor-free blood relatives and 22 spouses. The families had: malignant melanoma; Epstein-Barr virus-associated malignancies and a birth defect syndrome; non-Hodgkin lymphoma and diverse carcinomas; Hodgkin's lymphoma and adenocarcinomas; and acute myelogenous leukemia. In addition to the Philadelphia chromosome in chronic myelogenous leukemia patients, karyotypic abnormalities, especially breaks and fragments, were found in 29% of cancer family members, but were inconsistent and usually attributable to radiotherapy. Mean sister chromatid exchange values were normal in chronic myelogenous leukemia, but low (by t-test) in tumor patients and their blood relatives in cancer-prone families. In tumor patients, mean sister chromatid exchange levels fell as age increased. After adjusting for this age effect, no significant differences remained among groups. In patients at high risk of cancer (because they have chronic myelogenous leukemia or a strong family history of cancer), spontaneous sister chromatid exchange rates were not a marker of cancer risk.
 ...
PMID:Sister chromatid exchanges and chromosomes in chronic myelogenous leukemia and cancer families. 28 71

Among 246 patients (49 with Hodgkin's disease, 29 with multiple myeloma, 75 with other lympho- and immunoproliferative syndromes, 70 with carcinomas and 23 with non-malignant affections) treated by cytostatic or immunosuppressive chemotherapy, 6 developed malignant hemopathy (acute myeloblastic leukemia, erythroleukemia and erythremia) apparently induced during the last 7 1/2 years. In addition, 2 carcinomas have been noted. All have received melphalan or chlorambucil, alone or associated with other cytostatic drugs. 5 out of these 6 patients also underwent radiotherapy. The lenght of chemotherapy ranged between 7 and 110 months and the latency between 45 and 110 months. A "preleukemic" cytopenia phase was observed in 4 out of 6 cases. An exceptional 45-month survival was secured in case 1 (acute myeloblastic leukemia in a patient probably cured of Hodgkin's disease IIIB). Observation 2 is the 3rd case ever published of induced acute leukemia in disseminated lupus erythematosus. All these observations are compared with the latest findings in the literature. To the very extent that the utilization of cytostatic drugs produces improvement in the prognosis of very serious diseases, their leukemogenic potential becomes more dangerous and demands limitation of their use.
 ...
PMID:[Induced malignant hemopathies. 6 new cases with 1 patient surviving 45 months]. 28 15

A patient with Hodgkin's disease is reported in whom 5 years after establishing of diagnosis acute myeloid leukaemia developed during multistage treatment. The patient died. The authors discuss the problem of leukaemia-inducing influence of intensive radiotherapy and chemotherapy.
 ...
PMID:[Acute myeloid leukemia during Hodgkin's disease]. 28 73

Two children who presented initially with a lymphoid malignancy were noted to develop recurrences with myeloid features late in the course of their disease. In both cases, evidence of lymphoid differentiation was present in the myelogenous cells that were Ph1 chromosome negative. The first patient had acute myelogenous leukemia and developed a recurrence with morphologic features of acute myelogenous leukemia. Terminal transferase was present in the myelogenous blasts. The second patient initially had a diffuse lymphoblastic non-Hodgkin lymphoma. During the course of her illness she developed a myeloproliferative disorder characterized by basophilic meningitis, splenomegaly, and hypereosinophilia. Lymphocyte T-cell (E-rosette) markers were present on the eosinophils. These observations lend further support to the hypothesis of varying lymphoid and myeloid differentiation in certain cases of leukemia.
 ...
PMID:Myelogenous leukemia evolving during the course of lymphoid malignancy in children. 29 24


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>